Synopsis: Three pharma stocks remain in focus after strong Q3 results, reporting healthy revenue growth and profit expansion on both a sequential and a year-on-year basis.
The pharmaceutical sector continues to witness earnings-driven momentum as companies report resilient Q3 FY26 performance, supported by strong domestic demand, export traction, and improved operational efficiencies across formulations and API segments. Investors are closely tracking pharma counters that delivered healthy revenue growth and profit expansion on both QoQ and YoY basis, reflecting margin stability and improving scale advantages. Here is the list of pharma stocks that came into focus today after Q3 results
Ipca Laboratories Ltd
Ipca Laboratories Ltd is a fully integrated pharmaceutical company manufacturing over 350 formulations and 80 APIs across therapeutic segments. Ranked among India’s top 20 pharma firms, nearly 79% of its API revenue comes from exports to 100+ countries. Strong backward integration supports cost efficiency and supply chain reliability. With a market capitalization of Rs 37,351 crore, the share of the company today closed at Rs 1,472.50 per share, down 0.20 percent from the previous day’s close.
QoQ View: The revenue from operations declined by 6.45 percent to Rs 2,392 crore in Q3 FY26 from Rs 2,556.50 crore in Q2 FY26, and PBT grew by 13.8 percent to Rs 445.98 crore in Q3 FY26 from Rs 391.58 crore in Q2 FY26. Accompanied by a net profit that grew by 28.41 percent to Rs 364.05 crore in Q3 FY26 from Rs 283.50 crore in Q2 FY26.
YoY View: The revenue from operations grew by 6.5 percent to Rs 2,392 crore in Q3 FY26 from Rs 2,245.37 crore in Q3 FY25, and PBT grew by 21.21 percent to Rs 445.98 crore in Q3 FY26 from Rs 367.92 crore in Q3 FY25. Accompanied by a net profit growth of 31 percent to Rs 364.05 crore in Q3 FY26 from Rs 277.53 crore in Q3 FY25, resulting in an EPS growth of 23.6 percent to Rs 12.09 per share in Q3 FY26.
Zenith Health Care Ltd
Incorporated in 1993, Zenith Healthcare Ltd is in the business of manufacturing pharmaceutical formulations in the forms of general and beta lactum Tablets, Capsules, Oral liquid, and Injectables. The company offers contract manufacturing of all dosage forms. With a market capitalization of Rs 18.11 crore, the share of the company closed at Rs 3.37 per share, up 0.65 from the previous close.
QoQ View: The revenue from operations grew by 9.25 percent to Rs 2.48 crore in Dec 2025 from Rs 2.27 crore in Sep 2025, and EBIDT grew by 64.7 percent to Rs 0.28 crore in Dec 2025 from Rs 0.17 crore in Sep 2025. Accompanied by a net profit that grew by 57.1 percent to Rs 0.22 crore in Dec 2025 from Rs 0.14 crore in Sep 2025.
Medico Remedies Ltd
Incorporated in 1994, Medico Remedies Ltd is a pharmaceutical formulation manufacturing and marketing company with a focus on antibiotic, anti-infective, beta-lactam penicillin, cephalosporin, anti-fungal, antimalarial, antiretroviral, anti-ulcer drugs, antacids, vitamins & supplements, hematinic, and other drugs viz.
With a market capitalization of Rs 388.95 crore, the shares of the company today closed at Rs 46.87 per share, down 1.64 percent from its previous day’s close.
QoQ View: The revenue from operations grew by 11.6 percent to Rs 58.7 crore in Dec 2025 from Rs 52.6 crore in Sep 2025, and EBIDT grew by 58.6 percent to Rs 4.33 crore in Dec 2025 from Rs 2.73 crore in Sep 2025. Accompanied by a net profit that grew by 11.7 percent to Rs 2.87 crore in Dec 2025 from Rs 2.57 crore in Sep 2025.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
